Stockscreener 앱 받기
19.41
4.35%
0.81
시장 영업 전:
19.29
-0.12
-0.62%
Moonlake Immunotherapeutics 주식(MLTX)의 최신 뉴스
MLTX (NASDAQ: MLTX) Form 144 shows proposed 150,000-share resale via UBS - Stock Titan
Insmed Drug Misses Primary Goal, Program Axed - Sahm
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN
Weekly Recap: Does MoonLake Immunotherapeutics have declining or rising EPSChart Signals & Free Reliable Trade Execution Plans - baoquankhu1.vn
MoonLake says lead drug shows durable response, eyes FDA filing - MSN
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value - TipRanks
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - AOL.com
BVF's departure from MoonLake suggests a shift towards high-beta rebalancing as institutions remain divided in their perspectives - Bitget
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - The Motley Fool
MLTX SEC FilingsMoonLake Immunotherapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
How MoonLake’s Phase 3 Sonelokimab HiSCR75 Data in HS Could Shape MoonLake Immunotherapeutics (MLTX) Investors - simplywall.st
MoonLake Immunotherapeutics (MLTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
MoonLake’s lead asset shows durability in late-stage HS studies - MSN
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa - Yahoo Finance
Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment - TipRanks
Bvf Partners P/Il Sells 3,750,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat
BVF-linked MoonLake (MLTX) holder trims stake by 3.75M shares - Stock Titan
MoonLake (MLTX) holder BVF sells shares but keeps 22.3% stake - Stock Titan
MLTX Stock Jumps Overnight: Lead Skin Disease Drug Delivers Strong Phase 3 Gains With Majority Of Patients Improving - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 12.8%Here's Why - MarketBeat
Form 144 | MoonLake Immunotherapeutics(MLTX.US) 10% Stockholder Proposes to Sell 63.49 Million in Common Stocks - Moomoo
Affiliate sale notice: 3,750,000 shares proposed (NASDAQ: MLTX) - Stock Titan
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MoonLake Immunotherapeutics Jumps 9.6% During the Day Amid Positive Developments and Analyst Rating Increases - Bitget
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - Moomoo
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.7%Here's What Happened - MarketBeat
Cantor Fitzgerald reiterates Moonlake stock rating on regulatory outlook By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Moonlake stock rating on regulatory outlook - Investing.com
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After A Premium Price To Book Multiple And Recent Share Moves - simplywall.st
Research Analysts Issue Forecasts for MLTX Q1 Earnings - MarketBeat
Precision Trading with Moonlake Immunotherapeutics (MLTX) Risk Zones - Stock Traders Daily
What's Going On With MoonLake Stock Monday?MoonLake (NASDAQ:MLTX) - Benzinga
MoonLake and Incyte progress HS prospects at AAD - The Pharma Letter
BTIG reiterates Moonlake stock rating on hidradenitis suppurativa data - uk.investing.com
BTIG reiterates Moonlake stock rating on hidradenitis suppurativa data By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from BTIG Research - MarketBeat
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40 - news.futunn.com
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
MoonLake Reveals New Sonelokimab HS Phase 3 Trial Results - The Clinical Trial Vanguard
MLTX Bounces on Week 40 Trial Data—Is This a Setup for a Gamma Squeeze Before H2 2026 BLA Deadline? - Bitget
MoonLake Immunotherapeutics (MLTX) Is Up 6.5% After Strong Week 40 Sonelokimab HS Data Release – Has The Bull Case Changed? - simplywall.st
AAD26: MoonLake, Incyte highlight deepening responses in long-term HS readouts - FirstWord Pharma
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial - TipRanks
Sonelokimab Demonstrates High HiSCR100 Rates and Durable Responses in Hidradenitis Suppurativa - Dermatology Times
MoonLake Immunotherapeutics officially released the 40-week key data from the phase III clinical trial of its innovative drug Sonelokimab for the treatment of moderate to severe hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) An - Bitget
MoonLake Immunotherapeutics Reports Positive Week 40 Results from Phase 3 VELA Trials of Sonelokimab in Moderate-to-Severe Hidradenitis Suppurativa - Quiver Quantitative
MoonLake announces Week 40 Results from its Phase 3 - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) price target increased by 35.37% to 30.19 - MSN
1.57%
1.10%
자본화:
|
볼륨(24시간):